/

Workspace

Research & Review

Writing & Publishing

Data & Analysis

Utilities

Account

User Settings

G

Giuseppe Fornarini

Ospedale San Paolo(IT)

Claim or correct this author profile

Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.

297

Papers

4.6K

Citations

34

h-index

97

i10-index

Giuseppe Fornarini is an academic researcher from Ospedale San Paolo. The author has contributed to research in topics: Renal cell carcinoma treatment & Cancer Immunotherapy and Biomarkers & Prostate Cancer Treatment and Research. The author has an h-index of 34, co-authored 253 publications.

ORCID: 0000-0003-4754-6572

Research Topics

Renal cell carcinoma treatment Cancer Immunotherapy and Biomarkers Prostate Cancer Treatment and Research Cancer Genomics and Diagnostics Bladder and Urothelial Cancer Treatments

Papers by this author

works

Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer

2024 · New England Journal of Medicine · 810 citations

https://doi.org/10.1056/nejmoa2312117

Thomas Powles Begoña P. Valderrama Shilpa Gupta Jens Bedke

Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab

2019 · Clinical Cancer Research · 233 citations

https://doi.org/10.1158/1078-0432.ccr-18-3661

Ugo De Giorgi Giuseppe Procopio Diana Giannarelli Roberto Sabbatini

Immune-inflammatory biomarkers as prognostic factors for immunotherapy in pretreated advanced urinary tract cancer patients: an analysis of the Italian SAUL cohort

2021 · ESMO Open · 54 citations

https://doi.org/10.1016/j.esmoop.2021.100118

Giuseppe Fornarini Sara Elena Rebuzzi Giuseppe Luigi Banna Fabio Calabrò

Validation of the Meet-URO score in patients with metastatic renal cell carcinoma receiving first-line nivolumab and ipilimumab in the Italian Expanded Access Program

2022 · ESMO Open · 31 citations

https://doi.org/10.1016/j.esmoop.2022.100634

Sara Elena Rebuzzi Alessio Signori Sebastiano Buti Giuseppe Luigi Banna

LBA77 Fecal microbiota transplantation (FMT) versus placebo in patients receiving pembrolizumab plus axitinib for metastatic renal cell carcinoma: Preliminary results of the randomized phase II TACITO trial

2024 · Annals of Oncology · 30 citations

https://doi.org/10.1016/j.annonc.2024.08.2320

C. Ciccarese Serena Porcari Sebastiano Buti Giuseppe Fornarini

Multiple rare variants in high-risk pancreatic cancer-related genes may increase risk for pancreatic cancer in a subset of patients with and without germline CDKN2A mutations

2016 · Human Genetics · 26 citations

https://doi.org/10.1007/s00439-016-1715-1

Xiaohong R. Yang Melissa Rotunno Yanzi Xiao Christian Ingvar

Research topics

topics

Renal cell carcinoma treatment

Cancer Immunotherapy and Biomarkers

Prostate Cancer Treatment and Research

Cancer Genomics and Diagnostics

Bladder and Urothelial Cancer Treatments

Chat about Author

Papers

Chat

Click to start Chat